Skip to main content
. 2023 Jul 3;14:1227797. doi: 10.3389/fimmu.2023.1227797

Figure 3.

Figure 3

Anti-PD-1/PD-L1 inhibitors are approved by FDA for the treatment of lung cancer. The PD-1 inhibitors such as nivolumab, pembrolizumab, and cemiplimab and the PD-L1 inhibitors such as atezolizumab and durvalumab were illustrated in the panel. PD-1, programmed death 1; PD-L1, programmed death 1 ligand.